Oncology Pain Market Assessment
- Oncologist driven with < 100 oncology pain centers in U.S.
- Trend toward narcotics and aggressive pain treatment
- Market opportunity for Morphelan; no true once-a-day rapid onset sustained release product on the market
- Morphine remains gold standard